Thrombolytic drugs for heart attack

•	Encyclopedia Home
•	Special Topics A-Z
•	Read Spanish version

More Features

•	Printer-friendly version

Thrombolytic drugs for heart attack

Alternative Names

Myocardial infarction - thrombolytic; MI - thrombolytic; ST - elevation myocardial infarction; CAD - thrombolytic; Coronary artery disease - thrombolytic; STEMI - thrombolytic

Information

Small blood vessels called coronary arteries supply oxygen carrying blood to the heart muscle.

A heart attack can occur if a blood clot stops the flow of blood through one of these arteries.
Unstable angina refers to chest pain and other warning signs that a heart attack may happen soon. It is most often caused by blood clots in the arteries that partially block them.

Some people may be given drugs to break up the clot if the artery is completely blocked.

These drugs are called thrombolytics, or clot-busting drugs.
They are only given for a type of heart attack, where certain changes are noted on the ECG. This type of heart attack is called an ST segment elevation myocardial infarction (STEMI).
These drugs should be given as soon as possible after the chest pain first occurs (most often in less than 12 hours).
The medicine is given through a vein (IV).
Blood thinners taken by mouth may be prescribed later to prevent more clots from forming.

The main risk when receiving clot-busting drugs is bleeding, with the most serious being bleeding in the brain.

Thrombolytic therapy is not safe for people who have:

Bleeding inside the head or a stroke
Brain abnormalities, such as tumors or poorly-formed blood vessels
Had a head injury within the past 3 months
A history of using blood thinners or a bleeding disorder
Had major surgery, a major injury, or internal bleeding within the past 3 to 4 weeks
Peptic ulcer disease
Severe high blood pressure

Other treatments to open blocked or narrowed vessels that may be done in place of or after treatment with thrombolytic therapy include:

References

Bohula EA, Morrow DA. ST-elevation myocardial infarction: management. In: Libby P, Bonow RO, Mann DL, Tomaselli GF, Bhatt DL, Solomon SD, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 12th ed. Philadelphia, PA: Elsevier; 2022:chap 38.

Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. PMID: 28886621 pubmed.ncbi.nlm.nih.gov/28886621/.

Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(11):e771. PMID: 34882436 pubmed.ncbi.nlm.nih.gov/34882436/.

Review Date: 4/10/2023
Reviewed By: Michael A. Chen, MD, PhD, Associate Professor of Medicine, Division of Cardiology, Harborview Medical Center, University of Washington Medical School, Seattle, WA. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, timeliness, or correctness of any translations made by a third-party service of the information provided herein into any other language. © 1997- A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.